Paola Paterini

Paola Paterini

Auto-generated profile, based on publicly available information

Paola Paterini

Interdepartmental Centre for Cancer Research “G. Prodi”, University of Bologna, Bologna, Italy

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PSPasquale Sansone
Pasquale Sansone
GSGianluca Storci
Gianluca Storci
STSimona Tavolari
Simona Tavolari
Tiziana GuarnieriTiziana Guarnieri
Tiziana Guarnieri
CGCatia Giovannini
Catia Giovannini
MBMASSIMILIANO BONAFE'
MASSIMILIANO BONAFE'
High serum levels of IL-6 correlate with poor outcome in breast cancer patients. However, no data are available on the relationship between IL-6 and mammary stem/progenitor cells, which may fuel the genesis of breast cancer in vivo. Herein, we address this issue in the MCF-7 breast cancer cell line and in primary human mammospheres (MS), multicellular structures enriched in stem/progenitor cells of the mammary gland. MS from node invasive breast carcinoma tissues expressed IL-6 mRNA at higher levels than did MS from matched non-neoplastic mammary glands. In addition, IL-6 mRNA was detected only in basal-like breast carcinoma tissues, an aggressive breast carcinoma variant showing stem cell features. IL-6 treatment triggered Notch-3–dependent upregulation of the Notch ligand Jagged-1 and promotion of MS and MCF-7–derived spheroid growth. Moreover, IL-6 induced Notch-3–dependent upregulation of the carbonic anhydrase IX gene and promoted a hypoxia-resistant/invasive phenotype in MCF-7 cells and MS. Finally, autocrine IL-6 signaling relied upon Notch-3 activity to sustain the aggressive features of MCF-7–derived hypoxia-selected cells. In conclusion, these data support the hypothesis that IL-6 induces malignant features in Notch-3–expressing stem/progenitor cells from human ductal breast carcinoma and normal mammary gland.

1 May 2009 in Experimental Cell Research
Verified
Journal Article
Closed access
ASAntonio Strillacci
Antonio Strillacci
CGCristiana Griffoni
Cristiana Griffoni
PSPasquale Sansone
Pasquale Sansone
PPPaola Paterini
Paola Paterini
GPGiulia Piazzi
Giulia Piazzi
VTVittorio Tomasi
Vittorio Tomasi

1 September 2016 in Digestive and Liver Disease
Verified
Journal Article
Closed access
UVUmberto Volta
Umberto Volta
GCGiacomo Caio
Giacomo Caio
EBElisa Boschetti
Elisa Boschetti
FGFiorella Giancola
Fiorella Giancola
KRKerry J. Rhoden
Kerry J. Rhoden
Roberto De GiorgioRoberto De Giorgio
Roberto De Giorgio

24 April 2013 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
OGon behalf of GIST Study Group
on behalf of GIST Study Group
MPmaria pantaleo
maria pantaleo
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
Milena UrbiniMilena Urbini
Milena Urbini
MNMargherita Nannini
Margherita Nannini
GBGuido Biasco
Guido Biasco

1 January 2015 in World Journal of Clinical Cases
Verified
Journal Article
Open access
Francesco TovoliFrancesco Tovoli
Francesco Tovoli
CMChiara Masi
Chiara Masi
EGElena Guidetti
Elena Guidetti
GNGiulia Negrini
Giulia Negrini
PPPaola Paterini
Paola Paterini
LBLuigi Bolondi
Luigi Bolondi
Gluten is one of the most abundant and widely distributed components of food in many areas. It can be included in wheat, barley, rye, and grains such as oats, barley, spelt, kamut, and triticale. Gluten-containing grains are widely consumed; in particular, wheat is one of the world's primary sources of food, providing up to 50% of the caloric intake in both industrialized and developing countries. Until two decades ago, celiac disease (CD) and other gluten-related disorders were believed to be exceedingly rare outside of Europe and were relatively ignored by health professionals and the global media. In recent years, however, the discovery of important diagnostic and pathogenic milestones led CD from obscurity to global prominence. In addition, interestingly, people feeding themselves with gluten-free products greatly outnumber patients affected by CD, fuelling a global consumption of gluten-free foods with approximately $2.5 billion in United States sales each year. The acknowledgment of other medical conditions related to gluten that has arisen as health problems, providing a wide spectrum of gluten-related disorders. In February 2011, a new nomenclature for gluten-related disorders was created at a consensus conference in London. In this review, we analyse innovations in the field of research that emerged after the creation of the new classification, with particular attention to the new European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for CD and the most recent research about non-celiac gluten sensitivity.

28 May 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MPmaria pantaleo
maria pantaleo
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
MBMonica Di Battista
Monica Di Battista
MHMichael C. Heinrich
Michael C. Heinrich
PPPaola Paterini
Paola Paterini
GBGuido Biasco
Guido Biasco
Aberrations of the Insulin‐like Growth Factor (IGF) system have been found in association with a variety of cancer types. The potential role of IGF1R has been postulated in a small subset of GISTs, but until now the implications of its aberrations have not been defined. The aim of the study was to examine the IGF1R status in patients with gastric GIST in regard to KIT and PDGFRA genotype. Fresh resection specimens were collected from 8 primary tumours [2 wild‐type (WT) and 6 mutant cases]. IGF1R was studied as gene expression profiling with Affymetrix GeneChip HG‐U133Plus 2.0 arrays and as genomic copy number with SNP array analysis Affymetrix Genome Wide Human SNP 6.0 arrays, and at protein level with western blotting (WB) and immunohistochemistry (IHC). The unsupervised analysis of gene expression profiling of our patients merged with a data set from gastric GISTs identified 2 patients out of 8 with different expression of IGF1R. The data were confirmed by WB and IHC. In particular, IGF1R was upregulated in 2 young patients (<30‐years old), who had both WT disease and metastases at diagnosis. The SNP array analysis showed that none of the tumours had IGF1R amplification. GISTs are characterized by abnormalities of the KIT and PDGFRA receptors that affect prognosis and response to tyrosine kinase inhibitors. Both young adult with WT GIST had the over‐expression of IGF1R at mRNA and protein level. These results further confirm the hypothesis that IGF1R may be a potential therapeutic target in GISTs lacking KIT and PDGFRA mutations. © 2009 UICC